

# **SINGAPORE CARDIAC SOCIETY**



**Annual Report 2021/2022**


## NOTICE OF ANNUAL GENERAL MEETING 2022

---

Date : Sunday, 22<sup>nd</sup> May 2022  
Time : 1pm – 3pm  
Venue : Grand Hyatt Singapore, Gallery I & II, level 1

### AGENDA

1. Roll Call
2. To approve minutes of last Annual General Meeting (September 2021)
3. To approve Annual Report for 2021/2022
4. To approve Statement of Accounts for 2021
5. Proposal for investment
6. Proposed constitutional amendment for diverse representation in the SCS council
7. Election of Office Bearers for 2022/2023
8. Appointment of Honorary Auditors
9. To declare Presidency of Singapore Cardiac Society for 2022/2023
10. Any other business



**Adj A/Prof Chia Pow-Li**  
Honorary Secretary  
Singapore Cardiac Society

# PRESIDENT'S MESSAGE

---

Dear friends and colleagues,

On behalf of the Singapore Cardiac Society Council, I welcome you to the 2022 Annual General Meeting, our first live meeting in 3 years!

It is impossible to reflect upon this Council's past term without reference to the pandemic that has deeply disrupted everybody's lives, at times tragically, these past 2 years. The life and activity of our Society soldiers on nonetheless, and we are thankful for the resilience and resourcefulness shown by all who have toiled tirelessly to advance our mission to nurture cardiology education and collaboration.

Due to the delayed AGM in 2021, this present council has had a shortened 9-month run, but I believe it has been a very fruitful one. After our very successful ACC Asia conjoint meeting last year, much thought has gone into securing the financial future of our society. This is particularly pertinent given the recent ructions of the financial markets and expectations of a less benign inflation environment in the coming years. Our finance committee, who have generously contributed their time and wisdom, have devised an investment guideline to mitigate our losses to inflation and we hope to ratify this at our AGM.

The Diverse Representation constitutional amendment that was narrowly defeated at our last live AGM will be presented again with some modifications. We hope that we can pass this to ensure that our council will be protected from being dominated by the interests of any particularly large voting bloc within the Society.

Our Echocardiography, Interventional and ACC chapters are now well established and have produced a steady stream of high-quality webinars to help our members stay up to date with the latest developments in our field. We are truly grateful for the fraternity of regional and international Societies who continue to work closely with us.

The council has also been working on some new initiatives that we hope will blossom in the coming years. These include a nascent Women in Cardiology group, a revamping of our digital presence online and going paperless for our Society's work.

We would have just concluded another virtual Annual Scientific Meeting, which we earnestly hope will be the last online meeting. The restrictions on face-to-face meetings were lifted too late for us to pivot to a live meeting, though at least some live events were possible.

At our first live AGM in 3 years, we look forward to a post-pandemic world with hope and measured caution. The successful conclusion of this AGM will augur well for our next year, which will herald the 50<sup>th</sup> Anniversary of the Singapore Cardiac Society (unofficially, it will be our 65<sup>th</sup>). As it stands, our Annual Scientific Meeting in 2023 will also be our first live one since 2019, and it undoubtedly will be a joyous celebration of our Society's journey and the achievements of those who have been instrumental in its growth. It will also see us bring back the "social" in "society" as we learn to face this post-COVID-19 world with a quiet confidence, knowing well that the friendship, dedication and professionalism of our peers will see us through.

Thank you all for your unwavering support!



**Asst Prof Lim Toon Wei**  
President  
Singapore Cardiac Society

## COUNCIL MEMBERS AND BOARD OF TRUSTEES (SEPTEMBER 2021 – MAY 2022)



### 1<sup>st</sup> row left to right:

Dr Lim Toon Wei (President), Dr Yeo Tee Joo (Member), Prof Ding Zee Ping (Chair, Chapter of Echocardiography), Dr Jack Tan (Chair, Chapter of Interventional Cardiology)

### 2<sup>nd</sup> row left to right:

Dr David Foo (Vice-President), Dr Ong Hean Yee (Immediate Past-President), Dr Joshua Loh (Honorary Treasurer), Prof Koh Tian Hai (Trustee)

### 3<sup>rd</sup> row left to right:

Dr Yeo Khung Keong (Member), Dr Richard Ng (Trustee), Dr Colin Yeo (Honorary Auditor & Organising Chairman for 33<sup>rd</sup> ASM), Dr Edgar Tay (Member)

### 4<sup>th</sup> row left to right:

Dr Low Ting Ting (Member), Mr Lee Khuay Chye (Member, Finance Committee), Dr Kenny Sin (Trustee), Prof Tan Huay Cheem (Trustee)

### 5<sup>th</sup> row left to right:

Dr Chia Pow-Li (Honorary Secretary), Dr Tan Swee Yaw (Honorary Auditor), Dr Bernard Kwok (Chair, Finance Committee)

### Not in the picture:

Ms Kwa Kim-Li (Trustee)

# SINGAPORE CARDIAC SOCIETY

## ANNUAL SCIENTIFIC MEETINGS SINCE 1988

### Organising Chairmen and Theme

ASM	Year	Chairperson	Theme
1st	1988	Dr Arthur Tan	Update in Cardiology
2nd	1989	Dr Wu Dar Ching	Update in Cardiology
3rd	1990	Prof Chia Boon Lock	Singapore Cardiology in the 1990s
4th	1991	Dr Arthur Tan	What's New in Cardiology - 1990s and Beyond
5th	1992	Dr Richard Ng	Update on Cardiology 1992
6th	1993	Dr Lee Chuen Neng	Cardiology in Singapore: Current Status and Future Prospects
7th	1994	Dr Saw Huat Seong	Therapeutic Dilemmas in Cardiology
8th	1995	Dr Susan Quek	Contemporary Issues in Cardiac Management
9th	1996	Dr Christopher Chew	Cardiology in the New Millennium
10th	1997	Dr James Wong	Towards the Next Millennium on Cardiology and Cardiac Surgery
11th	1998	Dr Philip Koh	Into the Third Millennium A.D. Current Issues in Transition
12th	1999	Dr Lim Yean Teng	Cardiology in the 21st Century
N.A.	2000	Dr Terrance Chua	Cardiology 2000 AD: Past, Present & Future
13th	2001	Dr Tan Huay Cheem	Evidence Based Cardiology: The Millennium Challenge
14th	2002	Dr Ho Kheng Thye	The Expert Concensus Practice of Cardiology
15th	2003	Dr Tan Kok Soon	Changing the Course of Cardiovascular Diseases
16th	2004	Dr Lim Soo Teik	Controversies and Recent Advances in Cardiovascular Medicine
17th	2005	Dr James Yip	Cardiology: From Beginning to the End
18th	2006	Dr Tan Ru San	The Increasing Burden of Cardiovascular Disease in the Aging Population
19th	2007	Dr Kenny Sin	Cardiovascular Disease: The Metabolic Age
20th	2008	Dr Chuang Hsuan-Hung	Challenging the New Frontiers in Cardiovascular Disease
21st	2009	Dr Poh Kian Keong	Paradigm Shift in Cardiology: Impact on Practice
22nd	2010	Dr Victor Lim	Cardiology Today: Innovation, Application & Evolution
23rd	2011	Dr Ong Hean Yee	Preventing, Treating & Caring
24th	2012	Dr Ching Chi Keong	Cardiovascular Medicine: Living Longer and Better
25th	2013	Dr Chia Pow-Li	Emerging Challenges in Cardiovascular Care
26th	2014	Dr Chia Pow-Li	Best Patient Care with Modern Cardiology
27th	2015	Dr Joshua Loh	State-of-the-Art in Cardiovascular Care
28th	2016	Dr Joshua Loh	Advances in Cardiovascular Medicine: The Next 50 Years
29th	2017	Dr Joshua Loh	Multidisciplinary Approach to Cardiovascular Care
30th	2018	Dr Nadira Hamid	Future of Cardiology and Beyond
31st	2019	Dr Yeo Tee Joo	The Heart and Beyond: Integrated Approach to Holistic Care
	2020		Postponed to 2021 due to COVID-19 Pandemic
32nd	2021	Dr Yeo Tee Joo	ACC Asia 2021 together with SCS 32 <sup>nd</sup> Annual Scientific Meeting

# SINGAPORE CARDIAC SOCIETY

---

## ANNUAL SCIENTIFIC MEETINGS SINCE 1988

### Organising Chairmen and Theme

ASM	Year	Chairperson	Theme
33 <sup>rd</sup>	2022	Dr Colin Yeo	Advancing the frontiers of Cardiovascular Medicine

# SINGAPORE CARDIAC SOCIETY

## Annual Scientific Meetings - Singapore Cardiac Society Lecturers and Topics Since 1988

No.	S.C.S. Lecturer	Year	Topic
1	Dr Charles Toh	1988	National Cardiac Care in Singapore
2	Prof. Chia Boon Lock	1989	Ventricular Arrhythmias in Health and Diseases
3	Dr Tan Ngoh Chuan	1990	The Changing Face of Cardiothoracic Surgery
4	Dr Joseph Sheares	1991	Coronary Artery Bypass Graft Surgery: Venous Vs Arterial Conduits
5	Dr Richard Ng	1992	Coronary Angiography and Coronary Angioplasty (PTCA): A 12 year and 8 year experience and followup at Mount Elizabeth Hospital
6	Dr Wu Dar Ching	1993	New Developments in Cardiac Surgery
7	Dr Arthur Tan	1994	Controversies in Cardiology
8	Dr Maurice Choo	1995	Cardiology from the Beatles to the Boyz
9	Dr Low Lip Ping	1996	From Nitrates to Nitric Oxide: An Explosive Story
10	Dr Susan Quek	1997	The Story of Echocardiography - From Milestones to Challenges
11	Dr Saw Huat Seong	1998	Separating Science from Gimmickry
12	Dr Lee Chuen Neng	1999	The Trials and Tribulations of a Cardiac Surgeon
13	Dr Peter Yan	2001	Coronary Artery Disease 2001 AD - A Century of Advancement (Evidence-Based Strategies in Dealing with CAD in the 21st Century)
14	Dr Tong Ming Chuan	2002	Education, Discipline, Innovation - in the Cardiac World
15	Assoc Prof Koh Tian Hai	2003	Interventional Cardiology over the last 2 decades - Personal perspective
16	Assoc Prof Lim Yean Teng	2004	From Q-wave Myocardial Infarction to ST-Elevation Myocardial Infarction - New Wine for Old Bottle?
17	Dr C. Sivathanan	2005	Heart Devices: Rescue to Destination
18	Dr Terrance Chua	2006	Imaging for Ischaemia: Insights from Stress Scintigraphy
19	Dr Teo Wee Siong	2007	Role of Interventional Electrophysiology in Cardiology-Past, Present and Future
20	Assoc Prof Tan Huay Cheem	2008	Management of Coronary Artery Disease in the 21st Century
21	Assoc Prof William Yip	2009	Paediatric Cardiology in Singapore: A Personal Journey and Reflection
22	Dr Chua Yeow Leng	2010	Delirium Cordis, Hot Spots, Hot Wires and Mazes: The Story of Atrial Fibrillation
23	Dr Philip Wong	2011	Cardiovascular Translational Research; Bringing Ideas from Bench to Clinic
24	Assoc Prof Ling Lieng Hsi	2012	Mitral Valve Prolapse-The Past, Present and Future
25	Assoc Prof Lim Soo Teik	2013	The Changing Landscapes of Interventional Cardiology
26	Assoc Prof Kenny Sin	2014	Interventional Cardiology in the 21st Century: A Surgeon's Perspective
27	Assoc Prof Quek Swee Chye	2015	Advances in Paediatric Cardiovascular Medicine: The-State-of-Art
28	Assoc Prof Tan Ru San	2016	NOACs: Coming of Age
29	Assoc Prof Poh Kian Keong	2017	Contemporary Management of Aortic Stenosis and Beyond
30	Assoc Prof Ding Zee Pin	2018	65 Years of Echocardiography, Past, Present and Beyond
31	Assoc Prof James Yip	2019	The Evolution of Adult Congenital Heart Disease
			Postponed to 2021 due to COVID-19 Pandemic
32	Assoc Prof Aaron Wong	2021	Managing Coronary Artery Disease: New Paradigm and Beyond
33	Assoc Prof Yeo Tiong Cheng	2022	My 30 years love affair with Cardiology

# MINUTES OF ANNUAL GENERAL MEETING

---

## MINUTES OF ANNUAL GENERAL MEETING 2021

Held on Sunday, 19<sup>th</sup> September 2021 at 11.00 am via Zoom Platform

### **Present:**

Dr Ong Hean Yee	President
Dr Jack Tan	Immediate Past-President
Dr Lim Toon Wei	Vice-President
Dr David Foo	Honorary Secretary
Dr Joshua Loh	Honorary Treasurer
Dr Chia Pow-Li	Council Member
Dr Dinesh Nair	Council Member
Dr Tan Swee Yaw	Council Member
Dr Colin Yeo	Council Member
Dr Edgar Tay	Honorary Auditor
Dr Yeo Tee Joo	Honorary Auditor
Dr Koh Tian Hai	Trustee
Ms Kwa Kim Li	Trustee
Dr Richard Ng	Trustee
Dr Kenny Sin	Trustee
Dr Tan Huay Cheem	Trustee
Dr Bernard Kwok	Chairman, Finance Committee
Mr Lee Khuay Chye	Member, Finance Committee

### **Ordinary Members / Corresponding Member / Associate Members:**

Anand Ambhore	Lim Ing Haan
Chai Ping	Lim Soo Teik
Chao Victor	Lim Yean Teng
Chen Ruth	Lim Zhan Yun
Chen Zhengfeng Jason	Lin Weiqin
Chia Yew Woon	Ling Lee Fong
Chiam Paul	Loh Julian Kenrick Loh
Ching Chi Keong	Low Adrian
Ching Min Er	Low Ting Ting
Chong Daniel	Mohammed Rizwan Amanullah
Chong Victor	Mok Kwang How
Chow Jeremy	Ng Richard
Chow Weien	Ong Biau Chi
Chua Terrance	Ong Paul
Ding Zee Pin	Pinakin Parekh
Ewe See Hooi	Pipin Kojodjojo
Fahim Jafary	Poh Kian Keong
Fam Jiang Ming	Saket Subhash Junagade
Ho Hee Hwa	Saurabh Rastogi
Huang Wenjie	Seow Swee Chong
Ivandito Kuntjoro	Sia Ching Hui
K Gunasegaran	Sivaraj P Govindasamy
Keh Yann Shan	Syed Saqib Imran
Khoo Deanna	Tan Doreen
Lau Jeffrey	Tan Julian
Lee Chi Hang Ronald	Tan Kenny
Lee Evelyn	Tan Li Wei
Lee Jin Hyun Deborah	Thet Khaing
Lim Choon Pin	Tioh Christine



---

**Ordinary Members / Corresponding Member / Associate Members:**

Tong Jieli	Yeo Gerard
Tong Ming Chuan	Yeo Khung Keong
Kristanto William	Yeo Tiong Cheng
Wong Aaron	Yeo Wee Tiong
Wong Cliff	Yew Min Sen
Wong Raymond	Yip James
Yap Jonathan	Yong Quek Wei

Dr Ong Hean Yee, President of the Singapore Cardiac Society chaired the meeting.

**1. MINUTES OF LAST ANNUAL GENERAL MEETING**

The minutes of the last general meeting held on 27<sup>th</sup> September 2020 were read and unanimously approved. Dr Yeo Khung Keong proposed acceptance of the minutes and this was seconded by Dr Colin Yeo.

**2. TO APPROVE ANNUAL REPORT FOR 2020/2021**

Dr David Foo reported that there was a typo error for page 13 (Item 1-Office Bearers) of the Annual Report. It should be "At the Annual General Meeting held on 27 September 2020, the proposal to extend the tenure of current office bearers was passed" and not 27 September 2021.

Dr David Foo reported that the council held 4 council meetings virtually due to the COVID-19 pandemic.

Dr David Foo referred members to page 13 & 14 on new membership. There were 12 ordinary members, 3 associate members and 3 corporate members. There were 5 memberships upgraded from associate to ordinary. There were 2 memberships changed from ordinary to correspondence as they are now residing overseas. There were 4 resignations from ordinary members and 1 resignation from an associate member.

The Society did not award SCS Fellowship grants in 2021 due to the restriction on travel.

Pages 14 to 26 documents, 82 virtual CME events that were organized or endorsed by society from September 2020 to September 2021.

Dr Chia Pow-Li proposed acceptance of the Annual Report and this was seconded by Dr Tan Swee Yaw.

**3. STATEMENT OF ACCOUNTS 2020 FOR THE "SOCIETY"**

Dr Joshua Loh referred members to page 1, Statement by Executive Council, of the financial statements. He reported that the financial statements of society were drawn up so as to give a true and fair view of the state of affairs of the Society as at 31 December 2020.

In page 2, the Society's financial statements were audited by independent auditor, UHY Lee Seng Chan & Co. In the auditor's opinion, the accompanying financial statements were properly drawn up in accordance with the provisions of the Societies Act, Chapter 311 (the "Societies Act"), the Singapore Charities Act, Chapter 37 (the "Charities Act") and Financial Reporting Standards in Singapore (FRSs) so as to present fairly, in all material respects, the state of affairs of the Society as at 31 December 2020.

In page 5 of the financial statements, the total assets were \$3,011,971 and total liabilities were S\$248,011. The total net worth of the society stands at \$2,763,960. The net assets of S\$2,763,960 was allocated in various funds (Members' Fund-S\$318,499, Cardiology Advancement Fund (Capital fund)-S\$125,000, Cardiology Advancement Fund (General fund)-S\$2,074,551 and Singapore-APSC scholarship fund-S\$245,960).

---

Dr Joshua Loh mentioned that the Cardiology Advancement Fund was set up in 1984. The purpose and objective of the Fund is to sponsor scholarships, research projects, local cardiac conferences and workshops, and activities which would enhance the practice of cardiology in Singapore. The capital fund represents capital contribution of S\$125,000 set aside from the surplus derived from the 5<sup>th</sup> Asian Pacific Congress of Cardiology in 1972. The general fund consists of the surplus arising from the profit sharing of cardiology conferences at the agreed terms and conditions set among the parties involved in organising the conferences. Dr Joshua Loh reported that the Capital fund and General fund will be merged.

The Statement of Income and Expenditure was included in page 6 of the financial statements. The total income was \$98,326 in 2020, compared with S\$462,605 in 2019. The reason was because the Society did not organise the ASM in 2020. The total expenditure in 2020 was \$132,164 compared to S\$483,605 in 2019. There was a deficit of \$33,838 for 2020.

Dr Joshua Loh reported that the breakdown of the income can be found in page 19, note 11, of the financial statements. The 2 funds are "Members' fund" and "Cardiology Advancement Fund-General Fund". The Society received S\$15,959 from the government for its "Job Support Scheme".

***MEMBERS' FUND (\$49,090)***

The Society did not organise the "Annual Scientific Meeting" in 2020 due to pandemic, so there was no income in 2020. The "Membership subscriptions" were S\$32,160. The Society received an education grant of S\$3,600 from Vifor Pharma to organise a webinar. The contribution to the secretariat fee of S\$11,830 refers to the admin fee for application of CME events. The administrative fee of \$1,500 refers to the admin fee for the 3<sup>rd</sup> party sponsorship.

***CARDIOLOGY ADVANCEMENT FUND-General Fund (\$33,277)***

The income for fixed deposit interest was S\$33,277. There was no additional surplus from previous congresses.

Dr Joshua Loh referred members to note 13 (Expenditure), page 20 of the financial statements.

He reported that there was no expenditure on annual scientific meeting as the Society did not organise any ASM in 2020. The AGM expenses were higher compared to 2019 because the AGM was held separately in 2020. Unlike in previous years, the AGMs were usually held together with the ASM and the costs of running them were shared with the ASM.

The 'Entertainment, gifts, and refreshment' category saw a significant decrease, falling from S\$9,720 in 2019 to S\$1,945 in 2020. This was largely because the Society did not organise any events in 2020.

The Society subscribed to the Zoom platform, so there was an increase in "Subscription" from S\$4,471 in 2019 to S\$7,343 in 2020.

In 2020, the Society has one employee, and her employee benefits cost \$71,080.

Dr Joshua Loh recorded a vote of thanks to Mr Lee Khuay Chye for his financial advice. He also thanked Dr Bernard Kwok who has been appointed as the Chairman of the finance committee for a term of 3 years, with effect from 1<sup>st</sup> November 2020.

Dr Jack Tan asked if the society would be able to award more scholarships once the travelling restriction is lifted. Dr Ong Hean Yee replied that the society will definitely look into awarding more scholarships especially for the Singapore-APSC Scholarship fund that has been set aside.

Dr Koh Tian Hai suggested increasing the number of SCS scholarships too. Dr Ong Hean Yee replied that the Council would look into it.

Dr Richard Ng mentioned that the Society's financial position was still healthy despite the pandemic.

Dr Julian Tan proposed acceptance of the Statement of Accounts and this was seconded by Dr James Yip.

---

#### 4. ELECTION OF OFFICE BEARERS 2021/2022

- **PRESIDENT**

- (a) Dr Lim Toon Wei  
Proposer: Dr Chai Ping  
Secunder: Dr Pipin Kojodjojo

(b) Dr David Foo was proposed by Dr Jeremy Chow. Dr Dinesh Nair was proposed by Dr Jack Tan. In accordance to the SCS Constitution & Bye-Laws, the member must have previously served 2 years in Council to be eligible for this office. Both nominees did not fulfil this requirement and were not eligible for this office.

- (c) Dr Jack Tan was proposed by Dr Paul Ong and seconded by Dr Patrick Lim but he declined.
- (d) Dr Joshua Loh was proposed by Dr Jeremy Chow and seconded by Dr Julian Tan but he declined.
- (e) Dr Tan Swee Yaw was proposed by Dr Jack Tan and seconded by Dr Sivaraj Pillai Govindasamy but he declined.

Dr Richard Ng proposed nomination closed and Dr Aaron Wong seconded.

**Dr Lim Toon Wei was elected the President.**

- **IMMEDIATE PAST-PRESIDENT**

**Dr Ong Hean Yee will be the Immediate Past-President.**

- **VICE-PRESIDENT**

- (a) Dr David Foo  
Proposer : Dr Fahim Jafary  
Secunder : Dr Julian Tan
- (b) Dr Yeo Khung Keong  
Proposer : Dr Aaron Wong  
Secunder : Dr Sivaraj Pillai Govindasamy

- (c) Dr Joshua Loh was proposed by Dr Julian Tan but he declined.
- (d) Dr Edgar Tay was proposed by Dr Poh Kian Keong but he declined.

Dr Ong Hean Yee proposed nomination closed and Dr Chia Pow-Li seconded.

**Dr David Foo was elected the Vice-President.**

- **HONORARY SECRETARY**

- (a) Dr Yeo Khung Keong  
Proposer : Dr Tan Swee Yaw  
Secunder : Dr Jonathan Yap
- (c) Dr Chia Pow-Li  
Proposer : Dr Fahim Jafary  
Secunder : Dr Julian Tan

- (b) Dr Joshua loh was proposed by Dr Jeremy Chow but he declined.

Dr Kenny Sin proposed nomination closed and Dr Poh Kian Keong seconded.

**Dr Chia Pow-Li was elected the Honorary Secretary.**

---

- **HONORARY TREASURER**

- (a) Dr Joshua Loh  
Proposer: Dr Poh Kian Keong  
Secunder: Dr Fahim Jafary
- (b) Dr Yeo Khung Keong  
Proposer : Dr Fam Jiang Ming  
Secunder : Dr Keh Yann Shan

Dr Jack Tan proposed nomination closed and Dr Evelyn Lee seconded.

**Dr Joshua Loh was elected the Honorary Treasurer.**

- **COUNCIL MEMBERS**

- (a) Dr Tan Swee Yaw  
Proposer : Dr Yeo Khung Keong  
Secunder : Dr Ching Chi Keong
- (b) Dr Patrick Lim  
Proposer : Dr Chia Pow-Li  
Secunder : Dr Imran Syed
- (c) Dr Edgar Tay  
Proposer : Dr Jeremy Chow  
Secunder : Dr Patrick Lim
- (d) Dr Jonathan Yap  
Proposer : Dr Jack Tan  
Secunder : Dr Keh Yann Shan
- (e) Dr Yeo Tee Joo  
Proposer : Dr Raymond Wong  
Secunder : Dr Joshua Loh
- (f) Dr Yeo Khung Keong  
Proposer : Dr Sivaraj Pillai  
Secunder : Dr Pinakin V Parehk
- (g) Dr Ho Hee Hwa was proposed by Dr Fahim Jafary but he declined.
- (h) Dr Fam Jiang Ming  
Proposer : Dr Yeo Khung Keong  
Secunder : Dr Jonathan Yap
- (i) Dr Low Ting Ting  
Proposer : Dr Lin Weiqin  
Secunder : Dr Edgar Tay
- (j) Dr William Kristanto  
Proposer : Dr Saurabh Rastogi  
Secunder : Dr Yeo Tee Joo
- (k) Dr Chow Weien  
Proposer : Dr Jeremy Chow  
Secunder : Dr Jeffrey Lau
- (l) Dr Colin Yeo  
Proposer : Dr Ching Chi Keong  
Secunder : Dr Joshua Loh

(m) Dr Dinesh Nair was proposed by Dr Edgar Tay but he declined.

(n) Dr Poh Kian Keong  
Proposer : Dr Lim Toon Wei  
Secunder : Dr James Yip

Dr Cliff Wong proposed nomination closed and Dr Jeremy Chow seconded.

As there was a tie for Dr Yeo Tee Joo and Dr Tan Swee Yaw, Dr Ong Hean Yee requested members to submit their vote for the last Council member position.

**The four new Council members elected were Dr Low Ting Ting, Dr Edgar Tay, Dr Yeo Khung Keong and Dr Yeo Tee Joo.**

- **HONORARY AUDITORS**

- (a) Dr Colin Yeo  
Proposer : Dr Chia Pow-Li  
Secunder : Dr Joshua Loh
- (b) Dr Tan Swee Yaw  
Proposer : Dr Joshua Loh  
Secunder : Dr Aaron Wong
- (c) Dr William Kristanto  
Proposer : Dr Lim Toon Wei  
Secunder : Dr Chai Ping

Dr Joshua Loh proposed nomination closed and Dr Aaron Wong seconded.

**Dr Tan Swee Yaw & Dr Colin Yeo were elected the Honorary Auditors.**

#### **ANY OTHER BUSINESS**

- **Renewal of Term for Board of Trustees**

Dr Ong Hean Yee mentioned that the term of office for trustees has been renewed for another term of 3 years, with effect from 2020. They are Ms Kwa Kim Li, Dr Koh Tian Hai, Dr Richard Ng, Dr Kenny Sin and Dr Tan Huay Cheem.

- **ACC Asia 2021 together with SCS 32<sup>nd</sup> Annual Scientific Meeting**

Dr Yeo Tee Joo reported that the event was held from 9-11 July 2021 and was well attended by 810 registrants from 25 countries. There were 163 faculty members involved in the event. 139 abstracts were received from 23 countries.

The estimated profit was S\$433,250.00 before profit sharing with the American College of Cardiology (ACC) in the ratio of 50:50.

Dr Yeo Tee Joo thanked Dr Poh Kian Keong for being the main liaison person with ACC, Dr Ong Hean Yee and Dr Lim Toon Wei for their support, Dr Joshua Loh and Dr Chia Pow-Li for helping with commercial aspects, Dr Colin Yeo and Dr Julian Loh for the scientific committee, and Cherine.

- **Asian-Pacific Society of Cardiology (APSC) 2023**

Dr Yeo Tee Joo reported that the APSC is supposed to take place in Singapore in 2022. Due to COVID-19, Singapore will organize the APSC in 2023.

The planning committee members are Dr Jack Tan (APSC Congress Chair Central Committee In-charge), Dr Yeo Tee Joo (Organising Chairman), Dr Jonathan Yap (Scientific Chairman) and Dr Joshua Loh (Advisor).

The proposed dates will be in June or July 2023. The APSC 2023 will be held in conjunction with the Asian Pacific Society of Heart Failure.

The format will be an on-site meeting (safe-distancing measures permitting) and web-presence and content for hybrid meeting (depending on measures at the time of the meeting).

- **ASEAN Federation of Cardiology Congress (AFCC) 2024**

Dr David Foo reported that the AFCC 2020 was postponed to 14-16 November 2021 and will be organised virtually by Cambodia.

Thereafter, the Philippines will host AFCC 2022, Vietnam 2023, Singapore 2024, Myanmar 2025, and Malaysia 2026.

The Organising Committee members are Dr David Foo (Organising Chairman), Dr Yew Min Sen (Scientific Chairman), Dr Yeo Wee Tiong (Scientific Co-chair) and Dr Ho Kay Woon (Scientific Co-chair).

- **ACC Singapore Chapter**

Dr Edgar Tay reported that the ACC Singapore Chapter is working closely with the American College of Cardiology (ACC) for webinars. The Chapter plans to have 4 theme-based webinars in a calendar year. The Chapter has organised the following webinars:

- ✓ Updates in the Management of Tricuspid Valve Regurgitation  
Date: 17<sup>th</sup> October 2020  
Attendance: 246
- ✓ Lipid Lowering to Prevent Cardiovascular Events: State Of The Art 2021  
Date: 6<sup>th</sup> March 2021  
Attendance: 653  
Sponsor: Amgen
- ✓ Onco-Cardiology: Optimizing Cardiac Outcomes for Cancer Patients  
Date: 31<sup>st</sup> July 2021  
Attendance: 596  
Sponsor: Philips Singapore

**Upcoming Webinar**

- ✓ Surfing The Silver Years - Geriatric Cardiology 2021  
Date: 9<sup>th</sup> October 2021  
Sponsors: Pfizer Rare Disease & Edward Lifesciences

Dr Edgar Tay is planning for the Chapter's AGM to appoint a new Governor and Secretary-Treasurer position.

- **SCS Chapter of Interventional Cardiology**

Dr Joshua Loh reported that Chapter has been active in organising education events by the form of webinar from October 2020 to September 2021.

MONTH	TOPIC
9 October 2020	Champions League For Coronary Perforation
6 November 2020	Overcoming The Complexities In Left Main PCI
17 December 2020	Fellows Teaching Course: Save-a-Life!
7 January 2021	CCM® for Heart Failure – The Class Effect
5 February 2021	APSC CHAMPIONS LEAGUE: SAVE A LIFE! - My most memorable and best teaching case in STEMI care
4 March 2021	Sleep and Cardiology
6 March 2021	Transcontinental Chip Case Sharing Club - My Most Educational Case in COVID Pandemic Period
12 March 2021	Bifurcation Workshop
18 March 2021	Protecting AF Patients from Stroke: Guideline Updates and Management of Comorbidities
16 April 2021	Unusual causes and complications of Acute Coronary Syndromes
28 May 2021	Using OCT to Optimize the Treatment of Calcified Lesions
24 June 2021	Overcoming all Complexities: When the bleeding just doesn't stop
12 July 2021	How Should We Apply Omics on Cardiovascular Diseases to Clinical Medicine?
16 July 2021	Webinar Series with Live Cases

21 July 2021	APSC Consensus Recommendations on the use of MitraClip for Mitral Regurgitation: When, Who and How
12 August 2021	HF & Diabetes: Current landscape and the future
14 August 2021	Transcontinental Coronary Imaging and Physiology Club
2 September 2021	Fellows Teaching Course: Save-a-Life! Unusual Causes of MI

Dr Joshua Loh encouraged SCS members to join the Chapter as member. There is no separate membership fee for SCS members.

- **SCS Chapter of Echocardiography**

Dr Ding Zee Pin reported that the Chapter has resumed the Teaching programme for 2021.

MONTH	TOPIC	SPEAKER(S)
21 January	ECHO in Common Adult Congenital Heart Disease (ACHD)	Dr Lee Phong Teck
4 March	Athlete's Heart ECHO Jeopardy	A/Prof Tong Khim Leng & Dr Chow Weien
3 May	Pulmonary Hypertension	Dr Chan Po Fun
13 July	ECHO Assessment of Pericardial Disease	Dr Tong Jieli
6 September	Cardiac Amyloidosis	Dr Tan Li Ling
November		Dr Ling Lee Fong

#### Chapter's Educational Activities

- I. Vivid Talks Webinar - SUCCOUR\* Study: Myocardial Strain as a Replacement for EF in Surveillance for Cancer Therapeutic related Cardiotoxicity held on 29 March 2021
- II. Vivid Talks Webinar - Investigate new ways to assess LV function using strain with AI held on 19 April 2021
- III. The Chapter of Echo. and ASEAN Echo have jointly co-organized the ASEAN Echo Dialogues - Breaking Free of the Echo Chamber, held on 29 April 2021.
- IV. The Chapter participated in ECHO Asia 2021 held on 28-30 May 2021
- V. ASEAN Echo Dialogues | Part II: How to deal with Prosthetic Heart Valves – 24 June 2021

#### Upcoming Activities

- I. Echo In Practice 2021 – 24th & 25th September

- **International Society of Cardiovascular Pharmacotherapy (ISCP) 2021**

Dr Doreen Tan reported that the planning committee members were Dr Jack Tan (Organising Chairman), Dr Kenny Sin (Organising Co-Chair), Dr Doreen Tan (Scientific Chair) and Dr Mark Chan (Scientific Co-Chair).

Dr Doreen Tan reported that the ISCP 2021 was held from 24-25 July 2021 virtually. The event attracted 1776 participants (41% were Pharmacists and 21% were doctors) from 42 countries.

The ISCP managed to recruit 1192 new members.

- **Any Other Business**

There being no other business, the meeting closed at 1.40 pm.

**Dr Ong Hean Yee**  
President  
Singapore Cardiac Society

**Dr David Foo**  
Honorary Secretary  
Singapore Cardiac Society

# SINGAPORE CARDIAC SOCIETY

## Attendance for Council Meetings for 2021/2022

No.	Name	Title	21 October 2021	16 December 2021	17 February 2022	7 April 2022	Total mtg attended
1	Dr Lim Toon Wei	President	√	√	√	√	4
2	Dr Ong Hean Yee	Immediate Past-President	√	√	√	√	4
3	Dr David Foo	Vice President	√	√	√	√	4
4	Dr Chia Pow-Li	Honorary Secretary	√	√	√	√	4
5	Dr Joshua Loh	Honorary Treasurer	√	√	√	√	4
6	Dr Low Ting Ting	Council Member	√	√	√	√	4
7	Dr Edgar Tay	Council Member	√	√	√	√	4
8	Dr Yeo Khung Keong	Council Member	√	√	√	√	4
9	Dr Yeo Tee Joo	Council Member	√	√	√	√	4
10	Dr Tan Swee Yaw	Honorary Auditor	√	√	√	√	4
11	Dr Colin Yeo	Honorary Auditor	√	√	√	√	4
12	Prof Koh Tian Hai	Trustee	√	Other commitments	√	√	3
13	Ms Kwa Kim Li	Trustee	Other commitments	√	√	Other commitments	2
14	Dr Richard Ng	Trustee	√	√	√	√	4
15	Dr Kenny Sin	Trustee	√	√	√	√	4
16	Prof Tan Huay Cheem	Trustee	√	Other commitments	√	√	3
	<u>Special Invitation</u>						
17	Dr Bernard Kwok	Chairman, Finance Committee	√	√	√	Other commitments	3
18	Mr Lee Khuay Chye	Member, Finance Committee	√	√	√	√	4
20	Dr Ding Zee Pin	Pro Tem Chair, Echo Chapter	√	√	√	√	4
22	Dr Jack Tan	Pro Tem Chair, PCI Chapter	√	√	√	√	4
21	Dr Poh Kian Keong	Chia Boon Lock Cardiology Medal & Prize	√	—	—	—	1
22	Dr Yew Min Sen	Scientific Chairman, ASM 2022	—	—	√	—	1



# REPORT OF ACTIVITIES FOR 2021 – 2022

---

## 1. OFFICE BEARERS

At the Annual General Meeting held on 19<sup>th</sup> September 2021, the following members were elected to hold office in the Singapore Cardiac Society.

President	: Dr Lim Toon Wei
Immediate Past-President	: Dr Ong Hean Yee
Vice-President	: Dr David Foo
Honorary Secretary	: Dr Chia Pow-Li
Honorary Treasurer	: Dr Joshua Loh
Council Member	: Dr Low Ting Ting
Council Member	: Dr Edgar Tay
Council Member	: Dr Yeo Khung Keong
Council Member	: Dr Yeo Tee Joo
Honorary Auditor	: Dr Tan Swee Yaw
Honorary Auditor	: Dr Colin Yeo

## 2. COUNCIL MEETINGS

Council meetings were held on the following dates:

21<sup>st</sup> October 2021  
16<sup>th</sup> December 2021  
17<sup>th</sup> February 2022  
7<sup>th</sup> April 2022

## 3. NEW MEMBERS & RESIGNATION

*Membership of the Society was approved for the following:*

### **Ordinary Membership**

Dr Leow Khang Leng  
Dr Tan Wei Xian Alex  
Dr Anbalakan Kamalesh  
Dr Chew Yun Chi Kenneth Michael  
Dr Iswaree Balakrishnan  
Dr Wang Luo Kai  
Dr Ng Chee Keong  
Dr Wang Yi-Ting Laureen  
Dr Chiang Shu Qi Benita

### **Associate Membership**

Ms Luzvilla Anacta  
Dr Tan Tze Chin

*Resignation of the Society was accepted for the following:*

### **Associate Membership**

Ms Giselle Abad  
Ms Loh Yu Xuan

## 4. Asian-Pacific Society of Cardiology 2023

See Appendix I

## 5. ASEAN Federation of Cardiology Congress 2024

See Appendix II

---

## 6. Local Scientific Meetings

Local Scientific meetings organised included:

- 1 Ongoing Learning in Advanced Diabetes Treatment  
What's new at ESC 2021?  
Date: 12<sup>th</sup> September 2021  
Venue: Webinar  
Sponsor: Boehringer Ingelheim Singapore Pte Ltd  
Chairperson: Dr Lin Weiqin  
Speakers: Dato' Dr Azmee Mohd Ghazi  
Dr Subodh Verma
  
- 2 Role of SGLT2 in HFpEF and its Impact on Renal Outcomes  
Date: 29<sup>th</sup> September 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Dr James Xu  
Dr Chien Do Van
  
- 3 Small Vessel Disease  
Date: 15<sup>th</sup> October 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speaker: Datuk Dr Rosli Mohd Ali
  
- 4 Heart Failure Management – Reactive Treatment is now PROACTIVE Care  
Date: 22<sup>nd</sup> October 2021  
Venue: Webinar  
Sponsor: Boston Scientific Asia Pacific Pte Ltd  
Chairpersons: Dr David Foo  
Dr Derek Chin  
Speakers: Prof Angelo Auricchio  
Dr Grant Shalaby
  
- 5 LEQVIO CME Webinar  
Date: 23<sup>rd</sup> October 2021  
Venue: Webinar  
Sponsor: Novartis (Singapore) Pte Ltd  
Chairperson: Prof Tan Huay Cheem  
Speakers: Prof Kausik Ray  
Clin Assoc Prof Yeo Khung Keong  
Dr Peter Yan

- 
- 6 Evidence on the Management Pathway in T2D with CVD Risk and Renal Impairment  
Date: 23<sup>rd</sup>, 24<sup>th</sup> and 30<sup>th</sup> October 2021  
Venue: Webinar  
Sponsor: Boehringer Ingelheim Singapore Pte Ltd  
Chairpersons: Dr Jason Choo  
Dr Edgar Tay  
Dr Julian Loh  
Dr Ester Yeoh  
Dr Firdaus Hadi  
Dr Muhammad Iqbal  
Speakers: Prof Mark Petrie  
Dr Lee Zhen Vin  
Dr Matthew Tan  
Prof Lim Lee Ling  
Prof Janaka Karralliede  
Dr Roger Tan  
Prof Merlin Thomas  
Dr Yew Shiong Shiong  
Dr Danish Ng  
Prof Goh Su-Yen  
Dr Peter Lin  
Dr Goh Ping Ping  
Dr Lim Choon Pin  
Prof Andrew Coats  
Dr Patrick Tiau  
Dr Shalini C Sree Dharan  
Dr Ong Hean Yee  
Dr Vijaya Bharath
- 7 Cardiac Amyloidosis  
Date: 3<sup>rd</sup> November 2021  
Venue: Webinar  
Sponsor: Chapter of Echocardiography  
Speaker: Dr Ling Lee Fong
- 8 The Corpus ASCVD Programme  
Date: 9<sup>th</sup> November 2021  
Venue: Webinar  
Sponsor: Novartis Singapore Pte Ltd  
Speakers: Prof Francois Mach  
Clin Assoc Prof Tan Ru San  
Datin Dr Ong Mei Lin
- 9 eXperts' eXchange: Antithrombotic Therapies in AF patients Undergoing PCI  
Date: 11<sup>th</sup> November 2021  
Venue: Webinar  
Sponsor: Bayer (South East Asia) Pte Ltd  
Chairperson: Prof Tan Huay Cheem  
Speaker: Prof Roxana Mehran
- 10 Imaging from Simple to Complex PCI – LIVE Transmission from Sengkang Hospital and The Second Affiliated Hospital of Harbin Medical University  
Date: 12<sup>th</sup> November 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speaker: Prof Takashi Akasaka

- 
- 11 Heart Disease from Pandemic to Endemic  
Date: 13<sup>th</sup> & 20<sup>th</sup> November 2021  
Venue: Park Royal Pickering Hotel  
Sponsor: Servier Singapore Pte Ltd  
Chairpersons: Dr Stanley Chia  
Dr Tan Chong Hiok  
Speakers: Dr Jeremy Chow  
Dr Goh Ping Ping  
Dr Edgar Tay  
Dr Chan Wan Xian
- 12 All About Angina: Facts and Figures behind the Heartache  
Date: 26<sup>th</sup> November 2021  
Venue: Conrad Centennial Singapore  
Sponsor: Servier Singapore Pte Ltd  
Speaker: Dr Ong Jau Lueng Paul
- 13 CHIP with or without MCS (Mechanical Circulatory Support)  
Date: 27<sup>th</sup> November 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speaker: Asst Prof Kevin J. Croce
- 14 Launch of Jardiance HFREF indication: Ready to Ignite  
Date: 27<sup>th</sup> November 2021  
Venue: Webinar  
Sponsor: Boehringer Ingelheim Singapore Pte Ltd  
Chairperson: Dr Ong Hean Yee  
Speakers: Clin Assoc Prof David Sim  
Prof Andrew Coats
- 15 Cardio Summit 3.0  
Date: 20<sup>th</sup>, 27<sup>th</sup> November & 4<sup>th</sup> December 2021  
Venue: Webinar  
Sponsor: Sanofi-Aventis (Singapore) Pte Ltd  
Chairpersons: Dr Ng Wai Kiat  
Dr Lam Kai Huat  
Dr Gary Lee  
Speakers: Assoc Prof Dr Jack Tan  
Prof Dr Tse Hung Fat  
Prof Dr Dirk Sibbing  
Dr Kim Chan Joon  
Prof Dr Charles Chan  
Dr Roger Tan  
Assoc Prof Dr Jeyakantha Ratnasingam
- 16 ISAR-REACT 5 Study: TWILIGHT/TICO Trials and Implementation of P2Y12 Inhibitor Monotherapy Approach into Clinical Practice  
Date: 30<sup>th</sup> November 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Dr Derek Lee  
Dr Bernard Benjamin Albano
- 17 EMPORIUM [Evidence in the Management Pathway across heart Failure spectrum]  
Date: 8<sup>th</sup> December 2021  
Venue: Webinar  
Sponsor: Boehringer Ingelheim Singapore Pte Ltd  
Chairperson: Dr Lim Yean Teng  
Speakers: Dr Daniel Yeo  
Dr Lim Choon Pin

- 
- 18 APSC CME Webinar: Cardio Summit  
Date: 8<sup>th</sup> & 9<sup>th</sup> December 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Dato Dr David Chew  
Prof Rungroj Krittayaphong  
Prof Andrew Coats  
Prof Naveed Sattar  
Dr Rontgene Solante  
Prof Faiez Zannad  
Prof Frank Ruschitzka  
Prof David Sim  
Prof Jasper Tromp
- 19 Transcontinental Coronary Imaging and Physiology Club  
Date: 18<sup>th</sup> December 2021  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Dr Jung Min Ahn  
Dr Morten Kern  
Dr Adrian Low  
Dr Johnathan Sung  
Dr Zhen-Vin Lee  
Dr Eric K.Y. Chan
- 20 Myocardial Infarction & RAASI: Facts, Management, & NEW Angioplasty Techniques  
Date: 15<sup>th</sup> January 2022  
Venue: One Farrer Hotel  
Sponsor: Servier Pte Ltd  
Speaker: Dr Dinesh Nair
- 21 Congenital Heart Programme  
Date: 24<sup>th</sup> January 2022  
Venue: Webinar  
Sponsor: Chapter of Echocardiography  
Chairpersons: Clin Assoc Prof Tan Ju Le  
Dr Jonathan Choo  
Speakers: Dr Charmaine Chan  
Dr Foo Jie Sheng  
Dr Dyan Zhang  
Dr Yan Limin
- 22 Treatment of Worsening Heart Failure in Asia Pacific  
Date: 15<sup>th</sup> February 2022  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Prof Carolyn Lam  
Dr Daniel Yeo
- 23 High Bleeding Risk  
Date: 18<sup>th</sup> February 2022  
Venue: Webinar  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Prof Elvin Kedhi  
Dr Joshua Loh  
Dr Al-Fazir Omar

- 
- 24      Optimising Treatment of Hypertension and Cardiac Health in 2022  
Date:                    19<sup>th</sup> February 2022  
Venue:                   Grand Hyatt Singapore  
Sponsor:                Servier Singapore Pte Ltd  
Chairperson:           Dr Rohit Khurana  
Speakers:               Dr Rohit Khurana  
                              Dr Reginald Liew  
                              Dr Michael Macdonald
- 25      Heart Failure and COVID  
Date:                    23<sup>rd</sup> February 2022  
Venue:                   Webinar  
Sponsor:                Docquity Holdings Pte Ltd  
Chairperson:           Dr Ong Hean Yee  
Speakers:               Dr Ong Hean Yee  
                              Dr Gilbert C. Vilela
- 26      Impact of OCT Guided PCI on Decision Making and Outcomes  
Next Generation of OCT Champions  
Date:                    25<sup>th</sup> February 2022  
Venue:                   Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:           Clin Assoc Prof Jack Tan  
Speakers:               Prof Giulio Guagliumi  
                              Dr Hashrul Rashid  
                              Dr Nanda Iryuza  
                              Dr Dian Larasati Munawar  
                              Dr Lee Tjen Jhung  
                              Dr Kua Jieli  
                              Dr Liu Meng-Tsun  
                              Dr Sakolwat Montrivade
- 27      New Normal in Lipid Management in Primary Care Setting  
Date:                    26<sup>th</sup> February 2022  
Venue:                   Pan Pacific Singapore Hotel  
Sponsor:                Organon Singapore Pte Ltd  
Speaker:                 Dr Dinesh Nair
- 28      Early Recognition and Management of CaReMe factors  
Date:                    26<sup>th</sup> February 2022  
Venue:                   Webinar  
Sponsor:                AstraZeneca Singapore Pte Ltd  
Chairperson:           Dr Dinh Duc Huy  
Speakers:               Dr David Sim  
                              Dr Nemencio Nicodemus
- 29      Cardiovascular, Renal and Metabolic Benefits of SGLT2i in Type 2 Diabetes and Heart Failure  
Date:                    28<sup>th</sup> February 2022  
Venue:                   Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:           Clin Assoc Prof Jack Tan  
Speakers:               Dr Lucky Cuenza  
                              Dr Purich Surunchupakorn
- 30      Unusual Causes and Complications of Acute Coronary Syndromes  
Date:                    3<sup>rd</sup> March 2022  
Venue:                   Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:           Clin Assoc Prof Jack Tan  
Speaker:                 Prof Tan Huay Cheem

- 
- 31      Aortic Valve Replacement: Can we have our cake and eat it too?  
Date:                    5<sup>th</sup> March 2022  
Venue:                    Webinar  
Sponsor:                Association of Thoracic and Cardiovascular Surgeons of Asia  
Chairperson:            Asst Prof Weerachai Nawarawong  
Speakers:                Dr Kaushal Pandey  
                                  Dato' Seri Dr Jeffery Jeswant Dillon  
                                  Dr Yingqiang Guo
- 32      APSC ECG Case Competition  
Date:                    11<sup>th</sup> March 2022  
Venue:                    Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:            Clin Assoc Prof Jack Tan  
Speakers:                Dr Teng Lun En  
                                  Dr Annisa Prima Monika  
                                  Dr Goh Fang Qin  
                                  Dr Phang Yuen Hoong  
                                  Dr Julian Tay  
                                  Dr Chee Wei Shen  
                                  Dr Lien Cheng-Wei
- 33      APSC CME Webinar: MedMASTER  
The Latest Evidence for High Bleeding Risk PCI & Renal Denervation  
Date:                    18<sup>th</sup> March 2022  
Venue:                    Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:            Clin Assoc Prof Jack Tan  
Speakers:                Dr David Kandzari  
                                  Clin Assoc Prof Yeo Khung Keong  
                                  Dr Chin Chee Tang
- 34      Transcontinental CHIP Case Sharing Club – Women at the Helm  
Date:                    26<sup>th</sup> March 2022  
Venue:                    Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:            Clin Assoc Prof Jack Tan  
Speakers:                Dr Mirvat Alasnag  
                                  Dr Livia Gheorghe  
                                  Dr Carmen Ho  
                                  Dr Nicole Ryan  
                                  Dr Karen Shek  
                                  Dr Julia Stehli
- 35      APSC Cath Lab Workshop PCI in Diabetic Patient  
Date:                    1<sup>st</sup> April 2022  
Venue:                    Webinar  
Sponsor:                Asian Pacific Society of Cardiology  
Chairperson:            Clin Assoc Prof Jack Tan  
Speakers:                Dr Steve Vernon  
                                  Dr Ong Tiong Kiam
- 36      The Evolving LDL-C Management and What it means for Clinical Practice  
Date:                    6<sup>th</sup> April 2022  
Venue:                    Marriott Hotel ssoc  
Sponsor:                Novartis Singapore Pte Ltd  
Chairperson:            A/Prof Lim Yean Teng  
Speaker:                 Prof Ulrich Laufs

- 
- 37 Recognizing Coronary Artery Disease: A Deeper Look into its Management  
Date: 9<sup>th</sup> April 2022  
Venue: Conrad Centennial Singapore  
Sponsor: Servier Pte Ltd  
Speaker: Tan Eng Hock Melvin
- 38 Deep Dive into ACC 2022: Advances in Heart Failure Management  
Date: 25<sup>th</sup> April 2022  
Venue: NEST at One Farrer  
Sponsor: Novartis Singapore Pte Ltd  
Chairperson: Dr Pipin Kojodjojo  
Speaker: Prof Javed Butler
- 39 Cardiac Critical Care Programme  
Date: 25<sup>th</sup> April 2022  
Venue: Webinar  
Sponsor: Chapter of Echocardiography  
Speakers: Dr Robin Cherian  
Ms Amy Koh
- 40 Managing a Patient with Multiple Co-Morbidities  
Date: 29<sup>th</sup> April 2022  
Venue: The Famous Restaurant  
Sponsor: Novartis Singapore Pte Ltd  
Speaker: Dr Melvin Tan
- 41 The Optimal use of NOAC in Patients with Atrial Fibrillation  
Date: 30<sup>th</sup> April 2022  
Venue: Shangri-La Hotel, Dutch Pavilion  
Sponsor: A.Menarini Singapore Pte Ltd  
Chairperson: Dr Jeremy Chow  
Speakers: Prof Andreas Goette  
Dr Chao Tze Fan
- 42 “New Normal” in Lipid Management in Primary Care Setting  
Date: 7<sup>th</sup> May 2022  
Venue: Singapore Marriott Tang Plaza Hotel  
Sponsor: Organon Singapore Pte Ltd  
Speaker: Dr Ang Teck Kee
- 43 APSC Cath Lab Workshop: Beyond the Angiogram  
Date: 23<sup>rd</sup> May 2022  
Venue: Webcast  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Dr Andy Yong  
Dr Peter Ong  
Dr Bernard De Bruyne
- 44 Plaque Modification with IVUS Optimization  
Date: 24<sup>th</sup> May 2022  
Venue: Webcast  
Sponsor: Boston Scientific Asia Pacific Pte Ltd  
Chairperson: Prof Koh Tian Hai  
Speakers: Dr Kenichi Sakakura  
Dr Fahim H Jafary  
Dr Yeo Khung Keong  
Dr Wong Ningyan  
Dr Chin Chee Tan



- 
- 45 APSC Journal Club Series 2022-Hot Topics in Cardiology  
TAVI for Severe Aortic Stenosis: Insights from Latest Trials  
Date: 25<sup>th</sup> May 2022  
Venue: Webcast  
Sponsor: Asian Pacific Society of Cardiology  
Chairperson: Clin Assoc Prof Jack Tan  
Speakers: Dr Ivan Wong  
Dr F Aaysha Cader
- 46 Nightmares in the Cathlab  
Date: 2<sup>nd</sup> June 2022  
Venue: Swissotel  
Sponsor: Medtronic International Limited  
Chairperson: Clin Assoc Prof Aaron Wong  
Speakers: Dr Saket Junagade  
Dr Jason Chen  
Dr Muhammad Bin Idu Jion
- 47 New Normal in Lipid Management in Primary Care Setting  
Date: 16<sup>th</sup> July 2022  
Venue: Park Royal Collection  
Sponsor: Organon Singapore Pte Ltd  
Speaker: Dr Devinder Singh

## APPENDIX I

---

### ASIAN PACIFIC SOCIETY OF CARDIOLOGY CONGRESS (APSC) 2023

The Singapore Cardiac Society will host the Asian Pacific Society of Cardiology (APSC) Congress in Singapore from 13-15 July, 2023.

#### Format

First in-person APSC congress since the start of the COVID-19 pandemic, to allow healthcare providers to attend and interact with each other face to face.

#### Venue

The congress will be held at the Raffles City Convention Centre (RCCC).

#### Scientific Programme

12 July 2023 : Pre congress  
13 to 15 July 2023 : Main Congress  
16 July 2023 : Post Congress

#### Committee

Jack TAN, Chair, APSC Congress Central  
Organising Committee  
Tee Joo YEO, Chair, APSC 2023

Jonathan YAP, Scientific Chair, APSC 2023

Wei qin LIN, Scientific Co-Chair, APSC 2023

Colin YEO, Co-Chair, APSC 2023

Joshua LOH, Advisor, APSC 2023

#### Report by Tee Joo YEO

Chair, APSC 2023 Organising Committee

## APPENDIX II

---

### ASEAN FEDERATION OF CARDIOLOGY CONGRESS (AFCC) 2024

The Singapore Cardiac Society will be hosting the ASEAN Federation of Cardiology Congress (AFCC) in 2024.

Philippines will organise the AFCC in November 2022 followed by Vietnam in 2023.

#### The Organising Committee comprises the following members:

Organising Chairman: Dr David Foo  
Chairman, Scientific: Dr Yew Min Sen

#### **Track Champions:**

Intervention/Structural Heart	Dr Ho Kay Woon / Dr Jonathan Yap
Heart Rhythm	Dr Yeo Wee Tiong / Dr Elaine Boey
Critical Care	Dr Chia Yew Woon / Dr Ruth Chen
Multi-modality Imaging	Dr Jason See / Dr Goh Yun Yun
Heart Failure	Dr Ching Min Er / Dr Lin Wei qin
Preventive Cardiology/Cardiac Rehab	To be confirmed
Social	Dr Pinakin

The AFCC2024 is expected to attract 2000 participants from the Asia Pacific region. More information will be updated to the Council and Members soon.

#### Adj Assoc Prof David Foo

Chair, Organising Committee, AFCC 2024

**SINGAPORE CARDIAC SOCIETY, THE**  
**UEN No. S73SS0041**

**(Registered under the Societies Act 1966 Singapore)**  
**FINANCIAL STATEMENTS**

**31 December 2021**



**UHY LEE SENG CHAN & CO**  
**Public Accountants and**  
**Chartered Accountants**

**SINGAPORE CARDIAC SOCIETY, THE**  
**UEN No. S73SS0041A**

**GENERAL INFORMATION**

**Executive Council**

President	: Asst Prof Lim Toon Wei
Immediate Past-President	: Dr Ong Hean Yee
Vice President	: Adj Assoc Prof David Foo
Honorary Treasurer	: Dr Joshua Loh
Honorary Secretary	: Adj Asst Prof Chia Pow-Li
Honorary Auditors	: Clin Assoc Prof Tan Swee Yaw : Clin Asst Prof Colin Yeo
Council Members	: Asst Prof Low Ting Ting : Dr Edgar Tay : Clin Assoc Prof Yeo Khung Keong : Asst Prof Yeo Tee Joo
Independent Auditor	: UHY Lee Seng Chan & Co

**SINGAPORE CARDIAC SOCIETY, THE**  
**UEN No. S73SS0041A**

**FINANCIAL STATEMENTS**

**CONTENTS**

	Page
Statement by Executive Council	1
Independent Auditor's Report	2 - 4
Statement of Financial Position	5
Statement of Income and Expenditure and Other Comprehensive Income	6
Statement of Changes in Funds	7
Statement of Cash Flows	8
Notes to the Financial Statements	9 - 26

**SINGAPORE CARDIAC SOCIETY, THE  
(Registered in Singapore)**

**STATEMENT BY EXECUTIVE COUNCIL**

In the opinion of the Executive Council, the Society financial statements of Singapore Cardiac Society, The (the "Society") are drawn up so as to give a true and fair view of the state of affairs of the Society as at 31 December 2021, and of its results, changes in funds and cash flows of the Society for the financial year ended on that date and, at the date of this statement, there are reasonable grounds to believe that the Society will be able to pay its debts as and when they fall due.

On behalf of the Executive Council,



---

Asst Prof Lim Toon Wei  
President



---

Dr Joshua Loh  
Honorary Treasurer

Singapore

25 April 2022

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SINGAPORE CARDIAC SOCIETY, THE**

### **Report on the Audit of the Financial Statements**

#### **Opinion**

We have audited the financial statements of Singapore Cardiac Society, The (the "Society"), which comprise the statement of financial position as at 31 December 2021, and the statement of income and expenditure and other comprehensive income, statement of changes in funds and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements are properly drawn up in accordance with the provisions of the Societies Act 1966 (the "Societies Act"), the Singapore Charities Act 1994 (the "Charities Act") and Financial Reporting Standards in Singapore (FRSs) so as to present fairly, in all material respects, the state of affairs of the Society as at 31 December 2021 and of its results, changes in funds and cash flows of the Society for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit in accordance with Singapore Standards on Auditing (SSAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Society in accordance with the Accounting and Corporate Regulatory Authority (ACRA) *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Other Information**

Executive Council is responsible for the other information. The other information comprises the information included in the Statement by Executive Council set out on page 1.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## **INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SINGAPORE CARDIAC SOCIETY, THE**

### **Executive Council's Responsibility for the Financial Statements**

The Executive Council is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Societies Act, the Charities Act and FRSs, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, the Executive Council is responsible for assessing the Society's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Society or to cease operations, or has no realistic alternative but to do so.

The Executive Council's responsibilities include overseeing the Society's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management Committee.




**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  
SINGAPORE CARDIAC SOCIETY, THE**

- Conclude on the appropriateness of the Executive Council's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Society's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Society to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Report on Other Legal and Regulatory Requirements**

In our opinion, the accounting and other records required to be kept by the Society have been properly kept in accordance with the provisions of the Societies Act and the Charities Act. There was no fund raising appeal during the financial year.



**UHY Lee Seng Chan & Co**  
Public Accountants and  
Chartered Accountants

**Singapore**  
25 April 2022

**SINGAPORE CARDIAC SOCIETY, THE**  
**STATEMENT OF FINANCIAL POSITION**  
31 December 2021

	Note	2021 \$	2020 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	3	588,610	645,538
Fixed deposits	4	2,331,973	2,332,610
Other receivables	5	37,659	32,098
Prepayments		6,805	1,725
		<u>2,965,047</u>	<u>3,011,971</u>
<b>Non-current assets</b>			
Property, plant and equipment	6	-	-
		<u>2,965,047</u>	<u>3,011,971</u>
<b>Total assets</b>		<u>2,965,047</u>	<u>3,011,971</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Other payables	7	27,530	248,011
		<u>27,530</u>	<u>248,011</u>
<b>Total liabilities</b>		<u>27,530</u>	<u>248,011</u>
<b>NET ASSETS</b>		<u>2,937,517</u>	<u>2,763,960</u>
<b>FUNDS</b>			
Members' fund	8	476,367	318,449
Cardiology advancement fund	9		
- Capital fund		125,000	125,000
- General fund		2,090,190	2,074,551
Singapore-APSC scholarship fund	10	245,960	245,960
		<u>2,937,517</u>	<u>2,763,960</u>
<b>Total funds</b>		<u>2,937,517</u>	<u>2,763,960</u>

The accompanying notes form an integral part of these financial statements

**SINGAPORE CARDIAC SOCIETY, THE**

**STATEMENT OF INCOME AND EXPENDITURE AND OTHER COMPREHENSIVE INCOME**

Financial year ended 31 December 2021

	Note	2021 \$	2020 \$ (Represented) (Note 19)
<b>Income</b>			
SCS Members' fund	11	241,799	49,090
SCS Echo Chapter fund	11	35,670	-
SCS Education fund	11	16,909	25,365
ACC Singapore Chapter fund	11	56,000	-
SCS PCI Chapter fund	11	7,500	-
Cardiology advancement fund			
- general fund	11	15,639	33,277
Other income	12	3,220	15,959
<b>Total income</b>		<b>376,737</b>	<b>123,691</b>
<b>Expenditure</b>			
SCS Members' fund	13	166,849	132,164
SCS Echo Chapter fund	13	6,421	-
SCS Education fund	13	8,591	37,652
ACC Singapore Chapter fund	13	21,319	-
<b>Total expenditure</b>		<b>203,180</b>	<b>169,816</b>
<b>Surplus/(Deficit) for the year, representing total comprehensive income/(loss) for the financial year</b>		<b>173,557</b>	<b>(46,125)</b>

The accompanying notes form an integral part of these financial statements

**SINGAPORE CARDIAC SOCIETY, THE**

**STATEMENT OF CHANGES IN FUNDS**

Financial year ended 31 December 2021

	Members' fund \$ (Note 8)	Capital fund \$ (Note 9)	General fund \$ (Note 9)	Singapore-APSC scholarship fund \$ (Note 10)	Total funds \$
Balance at 1 January 2020	337,851	125,000	2,091,274	245,960	2,800,085
Deficit for the financial year, representing total comprehensive loss for the financial year	(79,402)	-	33,277	-	(46,125)
Transfer to operating fund	50,000	-	(50,000)	-	-
Payment of seed money	10,000	-	-	-	10,000
Balance at 31 December 2020	318,449	125,000	2,074,551	245,960	2,763,960
Surplus for the financial year, representing total comprehensive income for the financial year	157,918	-	15,639	-	173,557
Balance at 31 December 2021	476,367	125,000	2,090,190	245,960	2,937,517

The accompanying notes form an integral part of these financial statements

**SINGAPORE CARDIAC SOCIETY, THE**

**STATEMENT OF CASH FLOWS**

Financial year ended 31 December 2021

	Note	2021 \$	2020 \$ (Represented) (Note 19)
<b>Cash flows from operating activities</b>			
Surplus/(Deficit) for the financial year		173,557	(46,125)
Adjustments for:			
Depreciation of property, plant and equipment		-	328
Interest income		(10,226)	(33,277)
		<hr/>	<hr/>
Operating surplus/(deficit) before working capital changes		163,331	(79,074)
<b>Changes in working capital:</b>			
Other receivables		(8,663)	61,740
Prepayments		(5,080)	3,005
Other payables		(220,481)	116,836
		<hr/>	<hr/>
Net cash (used in)/from operating activities		(70,893)	102,507
		<hr/>	<hr/>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment		-	(328)
Changes in fixed deposits with maturity period of more than 3 months		637	(23,610)
Interest received		13,328	41,820
		<hr/>	<hr/>
Net cash from investing activities		13,965	17,882
		<hr/>	<hr/>
Net change in cash and cash equivalents		(56,928)	120,389
Cash and cash equivalents at beginning of financial year		645,538	525,149
		<hr/>	<hr/>
<b>Cash and cash equivalents at end of financial year</b>	3	<u>588,610</u>	<u>645,538</u>

The accompanying notes form an integral part of these financial statements

## **SINGAPORE CARDIAC SOCIETY, THE**

### **NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

These notes form an integral part of and should be read in conjunction with the Society financial statements.

#### **1. General information**

Singapore Cardiac Society, The (the "Society"), was registered under the Societies Act 1966 and as a charity under the Singapore Charities Act 1994 on 8 April 1994 with its registered office located at 81 Kim Keat Road, #08-00, Singapore 328836.

The principal activities of the Society are to advance the knowledge and practice of cardiology, promote research in cardiology, conduct conferences, workshops and other activities which will enhance the advancement of cardiology internationally and in Singapore.

The financial statements of the Society for the financial year ended 31 December 2021 were authorised for issue by the Executive Council on 25 April 2022.

#### **2. Summary of significant accounting policies**

##### **2.1 Basis of accounting**

The financial statements have been prepared in accordance with Financial Reporting Standards in Singapore ("FRSs") under the historical cost convention, except as disclosed in the accounting policies below.

The financial statements are presented in Singapore dollar ("S\$"), which is the functional currency of the Society.

The preparation of financial statements in conformity with FRS requires management to exercise its judgement in the process of applying the Society's accounting policies. It also requires the use of accounting estimates and assumptions. Although these estimates are based on management's best knowledge of current events and actions, actual results may ultimately differ from those estimates. Management is of the opinion that there are no areas involving critical judgements and no areas where estimates and assumptions are significant to the financial statements.

On 1 January 2021, the Society adopted the new or amended FRS and Interpretations of FRS ("INT FRS") that are mandatory for application for the financial year. Changes to the Society's accounting policies have been made as required, in accordance with the transitional provisions in the respective FRS and INT FRS.

The adoption of these new or amended FRS and INT FRS did not result in substantial changes to the Society's accounting policies and had no material effect on the amounts reported for the current or prior financial years.

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**2. Summary of significant accounting policies (continued)**

**2.2 Financial instruments**

**(a) Financial assets**

**Initial recognition and measurement**

Financial assets are recognised when, and only when the Society becomes party to the contractual provisions of the instruments.

At initial recognition, the Society measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Trade receivables are measured at the amount of consideration to which the Society expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant financing component at initial recognition.

**Subsequent measurement**

*Investments in debt instruments*

Subsequent measurement of debt instruments depends on the Company's business model for managing the asset and the contractual cash flow characteristics of the asset. The three measurement categories for classification of debt instruments are amortised cost, fair value through other comprehensive income (FVOCI) and fair value through profit or loss (FVPL). The Society only has debt instruments at amortised cost.

Financial assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Financial assets are measured at amortised cost using the effective interest method, less impairment. Gains and losses are recognised in profit or loss when the assets are derecognised or impaired, and through the amortisation process.

**Derecognition**

A financial asset is derecognised where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or loss that had been recognised in other comprehensive income for debt instruments is recognised in profit or loss.

## **SINGAPORE CARDIAC SOCIETY, THE**

### **NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

## **2. Summary of significant accounting policies (continued)**

### **2.2 Financial instruments (continued)**

#### **(b) Financial liabilities**

Financial liabilities are recognised when, and only when, the Society becomes a party to the contractual provisions of the financial instrument. The Society determines the classification of its financial liabilities at initial recognition.

All financial liabilities are recognised initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable transaction costs.

#### **Subsequent measurement**

After initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in profit or loss when the liabilities are derecognised, and through the amortisation process.

#### **Derecognition**

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. On derecognition, the difference between the carrying amounts and the consideration paid is recognised in profit or loss.

### **2.3 Impairment of financial assets**

The Society recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Society expects to receive, discounted at an approximation of the original effective interest rate.

The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is recognised for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).



**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**2. Summary of significant accounting policies (continued)**

**2.3 Impairment of financial assets (continued)**

The Society considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Society may also consider a financial asset to be in default when internal or external information indicates that the Society is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Society. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

**2.4 Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand and bank balances and short-term fixed deposits placed with banks which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents are presented net of fixed deposits with maturity period of more than three months.

**2.5 Property, plant and equipment**

All items of property, plant and equipment are initially recorded at cost. Subsequent to recognition, property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. The cost of property, plant and equipment includes its purchase price and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property, plant and equipment if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the property, plant and equipment.

Depreciation of property, plant and equipment is computed on a straight-line basis to allocate their depreciable amounts over their estimated useful lives as follows:

Computers	1 - 3 years
-----------	-------------

Fully depreciated property, plant and equipment are retained in the financial statements until they are no longer in use.

The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of the asset is included in profit or loss in the financial year the asset is derecognised.

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**2. Summary of significant accounting policies (continued)**

**2.6 Income recognition**

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Society and the revenue can be reliably measured, regardless of when the payment is made. Revenue is measured at the fair value of consideration received or receivable, taking into account contractually defined terms of payment and net of taxes and duty.

Membership subscriptions

Membership subscriptions are recognised when the members obtain the right to have access to the memberships.

Rendering of services

Revenue from rendering of services that are of short duration is recognised when the services are completed.

Sponsorship income

Sponsorship income received from members is recognised on receipt basis.

Interest income

Interest income is recognised using the effective interest method.

Government grants

Government grants that are receivable as compensation for expenses or losses incurred or for the purpose of giving immediate financial support to the Society are recognised in profit or loss as other income in the period in which they become receivable.

**2.7 Employee benefits**

**(a) Defined contribution plans**

The Society makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to defined contribution pension schemes are recognised as an expense in the period in which the related service is performed.

## **SINGAPORE CARDIAC SOCIETY, THE**

### **NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

## **2. Summary of significant accounting policies (continued)**

### **2.7 Employee benefits (continued)**

#### **(b) Short-term employee benefits**

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid if the Society has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

### **2.8 Provisions**

Provisions are recognised when the Society has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated reliably.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

### **2.9 Leases**

#### **Operating leases - where the Society is a lessee**

The Society adopts the exemption under FRS116 that the leases of office unit and office equipment are classified as low value assets.

Leases where a significant portion of the risks and rewards of ownership are retained by the lessors are classified as operating leases. Payments made under operating leases are taken to profit or loss on a straight-line basis over the period of the leases.

When an operating lease is terminated before the lease period has expired, any payment required to be made to the lessor by way of penalty is recognised as an expense in the period in which termination takes place.

### **2.10 Income tax**

No provision for taxation has been made in the financial statements as the Society is exempt from income tax under Section 13(1)(zm) of the Income Tax Act, Chapter 134.

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**3. Cash and cash equivalents**

	2021	2020
	\$	\$
Cash at banks and on hand	588,610	645,538

The Society opens bank accounts for international conference events on behalf of the event organisers. The bank accounts are held in trust for the respective conference event organisers which required the approval from the organising committees for any utilisation of the fund. The bank accounts will be closed upon the completion of the events.

At the end of the reporting period, no bank accounts held in trust for the international conferences are included in the cash and cash equivalents.

**4. Fixed deposits**

Fixed deposits with maturity period of 12 months (2020 : 12 months) and earn interest at 0.25% and 0.55% (2020 : 0.25% and 1.65%) per annum.

**5. Other receivables**

	2021	2020
	\$	\$
Interest receivable	4,337	7,439
Rental deposit	1,065	1,065
Seed funds for Educational Fund	10,000	10,000
Sundry receivables	22,257	13,594
	<u>37,659</u>	<u>32,098</u>

**SINGAPORE CARDIAC SOCIETY, THE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
 31 December 2021

**6. Property, plant and equipment**

	Computers	
	2021	2020
	\$	\$
<b>Cost</b>		
Balance at beginning	5,457	5,129
Addition	-	328
Balance at end	5,457	5,457
<b>Accumulated depreciation</b>		
Balance at beginning	5,457	5,129
Depreciation charge for the financial year	-	328
Balance at end	5,457	5,457
<b>Carrying amount</b>		
Balance at 31 December	-	-

**7. Other payables**

	2021	2020
	\$	\$
Advance receipt from Annual Scientific Meeting	1,591	194,547
Members subscription fee in advance	2,300	3,050
Provision for employee unutilised annual leave	4,613	4,456
APSC - Emirates scholarship payable	-	28,018
Accrued expenses	19,026	17,940
	27,530	248,011

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**8. Members' fund**

	SCS Members' fund \$	SCS Echo Chapter fund \$	SCS Education fund \$	ACC Singapore Chapter \$	SCS PCI Chapter \$	Total Members' funds \$
<b>2021</b>						
Balance at beginning	273,337	31,965	13,147	-	-	318,449
Surplus for the financial year	78,170	-	-	-	-	78,170
Receipts during the financial year	-	35,670	16,909	56,000	7,500	116,079
Payment for expenses during the financial year	-	(6,421)	(8,591)	(21,319)	-	(36,331)
Balance at end	351,507	61,214	21,465	34,681	7,500	476,367
<b>2020</b>						
Balance at beginning	290,382	31,965	15,504	-	-	337,851
Deficit for the financial year	(67,045)	-	(70)	-	-	(67,115)
Transfer from Cardiology Advancement General Fund	50,000	-	-	-	-	50,000
Receipt of seed fund	-	-	10,000	-	-	10,000
Receipt of education grant from members	-	-	25,365	-	-	25,365
Payment of education fund	-	-	(34,652)	-	-	(34,652)
Payment of administrative fee	-	-	(3,000)	-	-	(3,000)
Balance at end	273,337	31,965	13,147	-	-	318,449

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**9. Cardiology advancement fund**

The Cardiology Advancement Fund was set up in year 1984, the purpose and object of the Fund are to sponsor scholarships, research projects, local cardiac conferences and workshop and activities which would enhance the practice of cardiology in Singapore.

Capital fund

The capital fund represents capital contribution of \$125,000 set aside from the surplus derived from the 5<sup>th</sup> Asian Pacific Congress of Cardiology in 1972.

General fund

The general fund consists of the surplus arising from profit sharing of cardiology conferences at the agreed term and condition set among the parties involved for organising the conferences.

**10. Singapore-APSC Scholarship fund**

The Singapore-APSC scholarship fund consists of the surplus (US\$200,000) arising from profit sharing of APSC 2017 conference at the agreed term and condition set with Asian Pacific Society of Cardiology for the offering of a total 8 Singapore-APSC scholarships over the next 5 years, to provide excellent opportunities for promising in-training cardiology fellows from the Asia Pacific member countries to enhance their capabilities through mutual exchange and learning in Singapore.

	2021	2020
	\$	\$
Balance at 1 January	245,960	245,960
Payment of scholarship during the financial year	-	-
Balance at 31 December	<u>245,960</u>	<u>245,960</u>

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**11. Income**

	2021	2020
	\$	\$
<u>SCS Members' fund</u>		
Annual scientific meeting/ACC Asia 2021	210,472	-
Membership subscriptions	25,740	32,160
Educational grant for webinar	-	3,600
Contribution to secretarial fee	-	11,830
Administrative fee	5,587	1,500
	<hr/> 241,799	<hr/> 49,090
<u>SCS Echo Chapter fund</u>		
Sponsorship income	35,670	-
	<hr/>	<hr/>
<u>SCS Education fund</u>		
Receipt of education grant from members	16,909	25,365
	<hr/>	<hr/>
<u>ACC Singapore Chapter fund</u>		
Sponsorship income	56,000	-
	<hr/>	<hr/>
<u>SCS PCI Chapter fund</u>		
Sponsorship income	7,500	-
	<hr/>	<hr/>
Total members' fund	<hr/> <hr/> 357,878	<hr/> <hr/> 74,455
<u>Cardiology advancement fund - general fund</u>		
Surplus from HRAS - SCS GP Forum 2021	5,413	-
Fixed deposit interest income	10,226	33,277
	<hr/> 15,639	<hr/> 33,277
	<hr/> <hr/>	<hr/> <hr/>



**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**12. Other income**

	2021	2020
	\$	\$
Jobs support scheme	3,220	15,959
	<u>3,220</u>	<u>15,959</u>

Jobs Support Scheme (the “JSS”) is a temporary-scheme introduced in the Singapore Budget 2020 to help enterprises retain local employees. Under the JSS, employers will receive cash grants in relation to the gross monthly wages of eligible employees.

**13. Expenditure**

	2021	2020
	\$	\$
<u>SCS Members' fund</u>		
Accounting fee	4,000	3,500
AGM expenses	2,055	3,228
Audit fee	6,500	5,500
Bank charges	706	841
Chapter secretarial services	9,225	7,125
Cleaning expenses	-	100
Computer maintenance	49	120
Depreciation	-	328
Entertainment, gift and refreshment	6,464	1,945
Expenditure on ISCP 2021	18,551	-
General expenses	1,001	860
Medical expenses	407	230
Printing, postage and stationery	5,743	3,682
Office rental and utilities	4,680	4,721
Office insurance	182	-
Subscription	6,664	7,343
Staff welfare	2,206	2,330
Telecommunication	2,943	2,981
Transportation	2,464	2,307
Travelling	-	549
	<u>73,840</u>	<u>47,690</u>

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**13. Expenditure (continued)**

	2021	2020
	\$	\$
<u>Members' fund (continued)</u>		
Balance brought forward	73,840	47,690
Website expenses	825	1,025
Zoom subscriptions	4,140	-
Employee benefits expense		
- Salaries and bonus	75,006	71,080
- Central provident fund contribution	12,750	12,086
- Skill development levy	132	132
- Provision for annual leave entitlement	156	151
	<hr/>	<hr/>
	166,849	132,164
	<hr/>	<hr/>
<u>SCS Echo Chapter fund</u>		
Honorarium	5,413	-
Prizes	689	-
Bank charges	319	-
	<hr/>	<hr/>
	6,421	-
	<hr/>	<hr/>
<u>SCS Education fund</u>		
EURO PCI 2021	3,535	-
ESC Congress 2021	3,519	-
Administrative fee	1,500	3,000
Payment of education grants	-	34,652
Bank charges	37	-
	<hr/>	<hr/>
	8,591	37,652
	<hr/>	<hr/>
<u>ACC Singapore Chapter fund</u>		
Secretary supports	19,000	-
Graphic design	550	-
Speakers honorarium and gift	1,100	-
Working lunch	541	-
Postage	82	-
Bank charges	46	-
	<hr/>	<hr/>
	21,319	-
	<hr/>	<hr/>
Total members' fund expenditure	<hr/> <hr/>	<hr/> <hr/>
	203,180	169,816

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**14. Operating lease commitments - as lessee**

	2021	2020
	\$	\$
Operating lease expense for the financial year	5,484	5,484

The Society adopts the exemption under FRS116 that the leases of office unit and office equipment are classified as low value assets.

At the reporting date, the Society has outstanding commitments for minimum lease payments in respect of office unit and office equipment under non-cancellable operating leases falling due as follows:

	2021	2020
	\$	\$
Within one year	5,484	5,484
Between one and five years	6,301	10,609
	<u>11,785</u>	<u>16,093</u>

The above operating leases have tenure of 2 to 6 years. They do not contain any escalation clauses and do not provide for contingent rents.

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**15. Financial instruments by category**

At the reporting date, the aggregate carrying amounts of financial assets at amortised cost and financial liabilities at amortised cost were as follows:

	2021	2020
	\$	\$
Financial assets at amortised costs		
Cash and cash equivalents (Note 3)	588,610	645,538
Fixed deposits (Note 4)	2,331,973	2,332,610
Other receivables (Note 5)	37,659	32,098
	<u>2,958,242</u>	<u>3,010,246</u>
Financial liabilities at amortised cost		
Other payables excluding advance receipt (Note 7)	<u>23,639</u>	<u>50,414</u>

**16. Financial risk management**

The main risks arising from the Society's normal course of operation are credit, interest rate and liquidity risks. The Society's overall risk management strategy seeks to minimise potential adverse effects of these risks on the financial performance of the Society.

Risk management policies and procedures are reviewed regularly to reflect changes in market conditions and the Society's activities.

**Credit risk**

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis.

At the end of the reporting date, the maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statement of financial position. Cash is placed with banks which are regulated.

There is no financial asset that is past due and/or impaired.

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**16. Financial risk management (continued)**

**Interest rate risk**

Interest rate risk is the risk that the fair value of future cash flows of the Society's financial instruments will fluctuate because of changes in market interest rate.

The Society is exposed to interest rate risks through the impact of changes in interest rates on its fixed deposits.

**Sensitivity analysis**

At the end of the reporting period, an increase/decrease of 25 basis in interest rate of fixed deposit would increase/decrease net income for the financial year by \$5,830 (2020 : \$5,832).

**Liquidity risk**

Liquidity risk is the risk that the Society will encounter difficulty in meeting financial obligations due to shortage of funds.

The Society monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by Executive Council to finance its operations and to mitigate the effects of fluctuations in cash flows.

All financial liabilities in 2021 and 2020 are repayable on demand or due within one year from the end of the reporting period.

**Foreign currency risk**

Currency risk arises when transactions are denominated in foreign currencies.

The Society's exposure to foreign currency risk is not significant as its transactions are mainly in Singapore dollar.

**17. Fair values of financial instruments**

The Executive Council has determined that the carrying amounts of financial assets and liabilities approximate their fair values because these are short-term in nature

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**18. Capital management**

The Society defines “capital” to be funds received. The primary objective of the Society is to ensure that it maintains a healthy position through organising cardiology events and membership fee to sustain its operations.

There are no changes in the Society approach to capital management during the financial year. The Society is not subject to any externally imposed capital requirement.

**19. Comparative information**

During the financial year, certain comparative figures are also represented to conform with the current year’s presentation.

The financial impacts arising from the representation are as follows:

	2020 As previously reported \$	Adjustments \$	2020 As represented \$
<b>Statement of Income and Expenditure and Other Comprehensive Income</b>			
Income - Education fund	-	25,365	25,365
Expenditure - Education fund	-	(37,652)	(37,652)
Deficit for the year, representing total comprehensive loss for the year	(33,838)	(12,287)	(46,125)
<b>Statement of Cash flows</b>			
Deficit for the financial year	(33,838)	(12,287)	(46,125)
Net cash from operating activities	114,794	(12,287)	102,507
Receipts of education fund from members	25,365	(25,365)	-
Payment of education fund	(37,652)	37,652	-
Net cash used in other activities	(12,287)	12,287	-

**SINGAPORE CARDIAC SOCIETY, THE**

**NOTES TO THE FINANCIAL STATEMENTS**

31 December 2021

**20. Significant event**

Given the uncertainty over the length and severity of COVID-19, the financial outlook for the Society may be affected.

The Society is closely monitoring the development of COVID-19 and its impact on the Society's operations. In view of the continuing development and uncertainty of the COVID-19 situation, the full financial impact of the COVID-19 outbreak on the Society cannot be reasonably determined at this juncture.

**21. Standards issued but not yet effective**

The Society has not adopted the following standards applicable to the Society that have been issued but not yet effective:

Description	Effective for annual periods beginning on or after
Amendments to FRS 103 Reference to the Conceptual Framework	1 January 2022
Amendments to FRS16 Property, Plant and Equipment - Proceeds before Intended Use	1 January 2022
Amendments to FRS 37 Onerous Contracts - Cost of Fulfilling a Contract	1 January 2022
Annual Improvements to FRSs 2018 - 2020	1 January 2022
Amendment to FRS 1 Classification of Liabilities as Current or Non-current	1 January 2023

The Executive Council expect that the adoption of the above standards will have no material impact on the financial statements in the year of initial application.



## Singapore Cardiac Society

81 Kim Keat Road, #08-00, Singapore 328836

Tel: 6735 6580 Fax: 6735 3308 \* Email: [secretariat@singaporecardiac.org](mailto:secretariat@singaporecardiac.org) \* Website: [www.singaporecardiac.org](http://www.singaporecardiac.org)